{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:53Z","timestamp":1788265193223,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific and Technological Research Program of Chongqing Municipal Education Commission","award":["KJQN202100401, to Fan Yang"],"award-info":[{"award-number":["KJQN202100401, to Fan Yang"]}]},{"name":"Scientific and Technological Research Program of Chongqing Municipal Education Commission","award":["KJQN202100401, to Fan Yang"],"award-info":[{"award-number":["KJQN202100401, to Fan Yang"]}]},{"name":"Scientific and Technological Research Program of Chongqing Municipal Education Commission","award":["KJQN202100401, to Fan Yang"],"award-info":[{"award-number":["KJQN202100401, to Fan Yang"]}]},{"name":"Scientific and Technological Program of Basic Research and Achievement Transformation in Jiulongpo District of Chongqing","award":["2022-02-016-Y, to Yiru Shan"],"award-info":[{"award-number":["2022-02-016-Y, to Yiru Shan"]}]},{"name":"the Chongqing Talents Program","award":["cstc2024ycjh-bgzxm0095, to Bo Qin"],"award-info":[{"award-number":["cstc2024ycjh-bgzxm0095, to Bo Qin"]}]},{"name":"the Chongqing Talents Program","award":["cstc2024ycjh-bgzxm0095, to Bo Qin"],"award-info":[{"award-number":["cstc2024ycjh-bgzxm0095, to Bo Qin"]}]},{"name":"the Chongqing Talents Program","award":["cstc2024ycjh-bgzxm0095, to Bo Qin"],"award-info":[{"award-number":["cstc2024ycjh-bgzxm0095, to Bo Qin"]}]},{"name":"the Chongqing Talents Program","award":["cstc2024ycjh-bgzxm0095, to Bo Qin"],"award-info":[{"award-number":["cstc2024ycjh-bgzxm0095, to Bo Qin"]}]},{"name":"the Chongqing Natural Science Foundation of China","award":["CSTC2020JCYJ-MSXMX0221, to Bo Qin"],"award-info":[{"award-number":["CSTC2020JCYJ-MSXMX0221, to Bo Qin"]}]},{"name":"the Chongqing Natural Science Foundation of China","award":["CSTC2020JCYJ-MSXMX0221, to Bo Qin"],"award-info":[{"award-number":["CSTC2020JCYJ-MSXMX0221, to Bo Qin"]}]},{"name":"the Chongqing Natural Science Foundation of China","award":["CSTC2020JCYJ-MSXMX0221, to Bo Qin"],"award-info":[{"award-number":["CSTC2020JCYJ-MSXMX0221, to Bo Qin"]}]},{"name":"Program for Youth Innovation in Future Medicine, Chongqing Medical University","award":["W0101, to Fan Yang"],"award-info":[{"award-number":["W0101, to Fan Yang"]}]},{"name":"Program for Youth Innovation in Future Medicine, Chongqing Medical University","award":["W0101, to Fan Yang"],"award-info":[{"award-number":["W0101, to Fan Yang"]}]},{"name":"Program for Youth Innovation in Future Medicine, Chongqing Medical University","award":["W0101, to Fan Yang"],"award-info":[{"award-number":["W0101, to Fan Yang"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02689-8","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T07:39:41Z","timestamp":1742024381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Altered LY6E and TRIM6 expression in PBMCs correlated with HBsAg clearance and response to Peg-IFN-\u03b1 treatment in HBeAg-negative chronic hepatitis B patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Yiru","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"8","key":"2689_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2689_CR2","doi-asserted-by":"crossref","unstructured":"Songtanin B, Chaisrimaneepan N, Mend\u00f3za R et al. Burden, outcome, and comorbidities of extrahepatic manifestations in hepatitis B virus infections. Viruses. 2024;16(4).","DOI":"10.3390\/v16040618"},{"issue":"9","key":"2689_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"regional Global","year":"2022","unstructured":"Global regional, national burden of hepatitis B. 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10381","key":"2689_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepat B Lancet. 2023;401(10381):1039\u201352.","journal-title":"Hepat B Lancet"},{"issue":"6","key":"2689_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","volume":"76","author":"GLH Wong","year":"2022","unstructured":"Wong GLH, Gane E, Lok. A S F. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development? J Hepatol. 2022;76(6):1249\u201362.","journal-title":"J Hepatol"},{"key":"2689_CR6","doi-asserted-by":"crossref","unstructured":"Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(2).","DOI":"10.3390\/v14020434"},{"issue":"3","key":"2689_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/hep.21282","volume":"44","author":"K Wursthorn","year":"2006","unstructured":"Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus Adefovir induce strong CccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675\u201384.","journal-title":"Hepatology"},{"issue":"6","key":"2689_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/1389203043379378","volume":"5","author":"M Caraglia","year":"2004","unstructured":"Caraglia M, Vitale G, Marra M, et al. Alpha-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci. 2004;5(6):475\u201385.","journal-title":"Curr Protein Pept Sci"},{"issue":"1","key":"2689_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36\u201349.","journal-title":"Nat Rev Immunol"},{"key":"2689_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"2689_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/jmv.24659","volume":"89","author":"CN Hayes","year":"2017","unstructured":"Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses. J Med Virol. 2017;89(3):388\u201396.","journal-title":"J Med Virol"},{"key":"2689_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.virol.2022.12.014","volume":"579","author":"H Luo","year":"2023","unstructured":"Luo H, Hu X, Li Y, et al. The antiviral activity of tripartite motif protein 38 in hepatitis B virus replication and gene expression and its association with treatment responses during PEG-IFN-\u03b1 antiviral therapy. Virology. 2023;579:84\u201393.","journal-title":"Virology"},{"key":"2689_CR13","doi-asserted-by":"publisher","first-page":"106821","DOI":"10.1016\/j.micpath.2024.106821","volume":"194","author":"D Quan","year":"2024","unstructured":"Quan D, Wang P, Wu W, et al. Investigating the role of GTPase in inhibiting HBV replication and enhancing interferon therapy efficacy in chronic hepatitis B patients. Microb Pathog. 2024;194:106821.","journal-title":"Microb Pathog"},{"issue":"3","key":"2689_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/cmi.2016.67","volume":"15","author":"G Tan","year":"2018","unstructured":"Tan G, Xiao Q, Song H, et al. Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication. Cell Mol Immunol. 2018;15(3):272\u201381.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"2689_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2019.12.009","volume":"72","author":"YX Wang","year":"2020","unstructured":"Wang YX, Niklasch M, Liu T, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol. 2020;72(5):865\u201376.","journal-title":"J Hepatol"},{"issue":"9","key":"2689_CR16","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.3390\/ijms11093501","volume":"11","author":"H Chen","year":"2010","unstructured":"Chen H, Wang LW, Huang YQ, et al. Interferon-alpha induces high expression of APOBEC3G and STAT-1 in vitro and in vivo. Int J Mol Sci. 2010;11(9):3501\u201312.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2689_CR17","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1016\/j.celrep.2019.11.041","volume":"29","author":"G Tan","year":"2019","unstructured":"Tan G, Yi Z, Song H, et al. Type-I-IFN-Stimulated gene TRIM5\u03b3 inhibits HBV replication by promoting HBx degradation. Cell Rep. 2019;29(11):3551\u2013e35633553.","journal-title":"Cell Rep"},{"issue":"12","key":"2689_CR18","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1073\/pnas.93.12.5910","volume":"93","author":"M Mao","year":"1996","unstructured":"Mao M, Yu M, Tong JH, et al. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci U S A. 1996;93(12):5910\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2689_CR19","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1038\/s41467-018-06000-y","volume":"9","author":"KB Mar","year":"2018","unstructured":"Mar KB, Rinkenberger NR, Boys IN, et al. LY6E mediates an evolutionarily conserved enhancement of virus infection by targeting a late entry step. Nat Commun. 2018;9(1):3603.","journal-title":"Nat Commun"},{"issue":"7344","key":"2689_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481\u20135.","journal-title":"Nature"},{"issue":"7210","key":"2689_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature07207","volume":"455","author":"MN Krishnan","year":"2008","unstructured":"Krishnan MN, Ng A, Sukumaran B, et al. RNA interference screen for human genes associated with West nile virus infection. Nature. 2008;455(7210):242\u20135.","journal-title":"Nature"},{"issue":"7567","key":"2689_CR22","first-page":"144","volume":"525","author":"JW Schoggins","year":"2015","unstructured":"Schoggins JW, Wilson SJ, Panis M, et al. Corrigendum: A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2015;525(7567):144.","journal-title":"Nature"},{"issue":"7485","key":"2689_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nature12862","volume":"505","author":"JW Schoggins","year":"2014","unstructured":"Schoggins JW, MacDuff DA, Imanaka N, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 2014;505(7485):691\u20135.","journal-title":"Nature"},{"issue":"4","key":"2689_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tibs.2017.01.002","volume":"42","author":"S Hatakeyama","year":"2017","unstructured":"Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42(4):297\u2013311.","journal-title":"Trends Biochem Sci"},{"issue":"Pt 6","key":"2689_CR25","first-page":"1544","volume":"125","author":"T Sato","year":"2012","unstructured":"Sato T, Okumura F, Ariga T, et al. TRIM6 interacts with Myc and maintains the pluripotency of mouse embryonic stem cells. J Cell Sci. 2012;125(Pt 6):1544\u201355.","journal-title":"J Cell Sci"},{"key":"2689_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3389\/fmicb.2018.01611","volume":"9","author":"G Tan","year":"2018","unstructured":"Tan G, Song H, Xu F, et al. When hepatitis B virus Meets interferons. Front Microbiol. 2018;9:1611.","journal-title":"Front Microbiol"},{"issue":"8","key":"2689_CR27","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1371\/journal.pone.0070001","volume":"8","author":"S Zhang","year":"2013","unstructured":"Zhang S, Guo JT, Wu JZ, et al. Identification and characterization of multiple TRIM proteins that inhibit hepatitis B virus transcription. PLoS ONE. 2013;8(8):e70001.","journal-title":"PLoS ONE"},{"issue":"4","key":"2689_CR28","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"key":"2689_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2017.10.003","volume":"147","author":"M Han","year":"2017","unstructured":"Han M, Li Y, Wu W, et al. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Res. 2017;147:75\u201385.","journal-title":"Antiviral Res"},{"issue":"1","key":"2689_CR30","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Zhang K, Chen W, et al. Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs. Sci Rep. 2017;7(1):13383.","journal-title":"Sci Rep"},{"issue":"4","key":"2689_CR31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.22744","volume":"49","author":"R Moucari","year":"2009","unstructured":"Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49(4):1151\u20137.","journal-title":"Hepatology"},{"issue":"12","key":"2689_CR32","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","volume":"5","author":"HL Chan","year":"2007","unstructured":"Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5(12):1462\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2689_CR33","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tcb.2015.02.001","volume":"25","author":"MM Li","year":"2015","unstructured":"Li MM, MacDonald MR, Rice CM. To translate, or not to translate: viral and host mRNA regulation by interferon-stimulated genes. Trends Cell Biol. 2015;25(6):320\u20139.","journal-title":"Trends Cell Biol"},{"key":"2689_CR34","doi-asserted-by":"crossref","unstructured":"Mitra B, Wang J, Kim ES et al. Hepatitis B virus precore protein p22 inhibits alpha interferon signaling by blocking STAT nuclear translocation. J Virol. 2019;93(13).","DOI":"10.1128\/JVI.00196-19"},{"issue":"3","key":"2689_CR35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","volume":"60","author":"L Allweiss","year":"2014","unstructured":"Allweiss L, Volz T, L\u00fctgehetmann M, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol. 2014;60(3):500\u20137.","journal-title":"J Hepatol"},{"issue":"21","key":"2689_CR36","doi-asserted-by":"publisher","first-page":"12254","DOI":"10.1128\/JVI.00775-14","volume":"88","author":"J Hou","year":"2014","unstructured":"Hou J, van Oord G, Groothuismink ZM, et al. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection. J Virol. 2014;88(21):12254\u201364.","journal-title":"J Virol"},{"issue":"9","key":"2689_CR37","doi-asserted-by":"publisher","first-page":"e1005103","DOI":"10.1371\/journal.ppat.1005103","volume":"11","author":"SP Fletcher","year":"2015","unstructured":"Fletcher SP, Chin DJ, Gruenbaum L, et al. Intrahepatic transcriptional signature associated with response to Interferon-\u03b1 treatment in the woodchuck model of chronic hepatitis B. PLoS Pathog. 2015;11(9):e1005103.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2689_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/gutjnl-2017-314013","volume":"67","author":"E Thomas","year":"2018","unstructured":"Thomas E. Hepatitis B virus X protein: trimming antiviral defences in hepatocytes. Gut. 2018;67(1):3\u20134.","journal-title":"Gut"},{"issue":"1","key":"2689_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12859-023-05353-6","volume":"24","author":"X Zhang","year":"2023","unstructured":"Zhang X, Ma Y, Liu K, et al. Risk prediction for dermatomyositis-associated hepatocellular carcinoma. BMC Bioinformatics. 2023;24(1):222.","journal-title":"BMC Bioinformatics"},{"issue":"19","key":"2689_CR40","first-page":"4990","volume":"59","author":"N Kondoh","year":"1999","unstructured":"Kondoh N, Wakatsuki T, Ryo A, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 1999;59(19):4990\u20136.","journal-title":"Cancer Res"},{"issue":"5","key":"2689_CR41","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.55730\/1300-0144.5668","volume":"53","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yuan L, Cui S, et al. Tripartite motif protein 6 promotes hepatocellular carcinoma progression via multiple pathways. Turk J Med Sci. 2023;53(5):1032\u201344.","journal-title":"Turk J Med Sci"},{"issue":"2","key":"2689_CR42","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"EH Buster","year":"2008","unstructured":"Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained hbeag and HBsAg loss after long-term follow-up of hbeag-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135(2):459\u201367.","journal-title":"Gastroenterology"},{"issue":"4","key":"2689_CR43","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","volume":"20","author":"MJ Sonneveld","year":"2022","unstructured":"Sonneveld MJ, Park JY, Kaewdech A, et al. Prediction of sustained response after Nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: A multicenter study (CREATE). Clin Gastroenterol Hepatol. 2022;20(4):e784\u201393.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2689_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/apt.14376","volume":"47","author":"LY Mak","year":"2018","unstructured":"Mak LY, Wong DK, Cheung KS, et al. Review Article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47(1):43\u201354.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02689-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02689-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T19:13:50Z","timestamp":1742066030000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02689-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02689-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was received from Ethical Review Committee of the First Affiliated Hospital of Chongqing Medical University, Chongqing, China(Reference number: 2023\u2009\u2212\u2009311), and the registration process was successfully completed on the designated website (). All patients submitted written informed consent for their participation in the study. The study was conducted in adherence to relevant laws and institutional protocols and in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final version of the manuscript. Consent for the publication of data, images, or information was obtained from all participants (or their legal guardians) where applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}